934194
NanoFabTx™- PEG-RGD Lipid Mix
for synthesis of PEGylated RGD-functionalized liposomes
Synonyme(s) :
Liposome synthesis kit, Small molecule drug formulation kit
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352211
Produits recommandés
Niveau de qualité
Température de stockage
−20°C
Catégories apparentées
Application
About Targeted NanoFabTx™
Targeted NanoFabTX™- PEG-RGD Lipid Mix; for synthesis of PEGylated RGD targeted liposomes is a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEG-RGD targeted liposomes for the targeted delivery of the API to cancer cells.
Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins and peptides. This optimized lipid blend containg RGD peptide for targeted drug delivery and PEG to improve circulation time and impose stealth like behavior.
Application example:
Integrins (alpha V beta 3) are overexpressed by many cancer cells. The RGD peptide has high affinity to the integrins. Thus, liposomes containing the ligand RGD can be used to deliver the anti-cancer agent directly to the cancer cells. The targeted RGD liposomes will deliver the API to only the cancer cells and not the healthy cells. As a result, the targeted liposomes avoid off target effects which is a side effect of many anti-cancer therapies.
Targeted NanoFabTX™- PEG-RGD Lipid Mix; for synthesis of PEGylated RGD targeted liposomes is a ready-to-use nanoformulation lipid blend that includes lyophilized lipids and step-by-step instructions for synthesizing PEG-RGD targeted liposomes for the targeted delivery of the API to cancer cells.
Lipid-based formulations are widely used for drug delivery and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins and peptides. This optimized lipid blend containg RGD peptide for targeted drug delivery and PEG to improve circulation time and impose stealth like behavior.
Application example:
Integrins (alpha V beta 3) are overexpressed by many cancer cells. The RGD peptide has high affinity to the integrins. Thus, liposomes containing the ligand RGD can be used to deliver the anti-cancer agent directly to the cancer cells. The targeted RGD liposomes will deliver the API to only the cancer cells and not the healthy cells. As a result, the targeted liposomes avoid off target effects which is a side effect of many anti-cancer therapies.
Caractéristiques et avantages
- A ready-to-use lipid blend for the synthesis of PEG-RGD targeted liposomes.
- Step-by-step protocols (extrusion, microfluidics) developed and tested by our formulation scientists.
- Flexible synthesis tool to create uniform and reproducible liposomes.
- RGD ligand enables targeted drug delivery
- A lipid film hydration and extrusion protocol
- A microfluidics protocol using commercial platforms or syringe pumps
For more information, please refer to the protocol under the Protocol section of this page.
Informations légales
NanoFabTx is a trademark of Sigma-Aldrich Co. LLC
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells
Chen CW, et al.
International journal of nanomedicine, 6, 2567-2580 (2011)
RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer
Wang F, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 196, 222-233 (2014)
Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer
Sheikh A, et al.
Frontiers in Pharmacology, 12, 803304-803304 (2022)
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies
Tang Z, et al.
Drug design, development and therapy, 13, 3281-3290 (2019)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique